Diffuse Cardiac Uptake Misdiagnosed as Cardiac Amyloidosis in Bone Scan

In this presented case, a 77 years old woman suffering from ongoing knee pain underwent a bone scan using 99mTc-hydroxydiphosphonate (HDP) in suspicious for bone infection. An incidental finding from this scan revealed diffuse cardiac uptake, necessitating further diagnostic procedures to exclude the possibility of cardiac amyloidosis. In the subsequent 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scan and SPECT images, no perceptible cardiac uptake was observed at all. Upon retrospective review of the patient’s medical records, she had received 1000mg of ferric carboxymaltose for iron-deficient anemia, the day before the 99mTc-HDP bone scan. Therefore, it is assumed that the diffuse and temporary cardiac activity was due to the transient iron overload. We present and share this bone scan images in order to avoid possible future misinterpretation of cardiac amyloidosis.

Keywords:

Subject: Medicine and Pharmacology - Clinical Medicine

Figure 1.

We present a 77-year-old woman who suffered ongoing left knee pain after the prosthesis insertion. To evaluate the extent and severity of the periprosthetic bone infection, a bone scan using ^99mTc-hydroxydiphosphonate (HDP) was performed. Beyond the expected uptake in the left knee’s periprosthetic region, an incidental finding indicated a diffuse and moderate cardiac uptake (arrow). This finding was classified as grade 2, based on the visual grading system ranging from 0 to 3, proposed by Perugini for the diagnosis of cardiac amyloidosis in bone scan¹.

Figure 2.

A subsequent bone scan using ^99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) was obtained three weeks later including SPECT images for assessment of transthyretin-type cardiac amyloidosis (CA). The decision was influenced by the accumulating evidence that favored the use of ^99mTc-DPD over ^99mTc-HDP for detecting CA^2-4, and by the necessity of SPECT images. However, no perceptible radiotracer accumulation was observed in the subsequent ^99mTc-DPD scan (A). Additionally, no perceptible radiotracer uptake was noted in the myocardium on the axial SPECT images (B, C). An echocardiogram revealed preserved ejection fraction of 60% without any abnormal wall motion. No abnormality was found in serum free light chain, serum and urine protein electrophoresis/immunofixation data. Upon thorough review of her medical history, her hemoglobin level was 8.7 g/dl, and she was diagnosed with iron-deficient anemia. We also observed that a total of 1000mg of ferric carboxymaltose had been intravenously administered the day before the ^99mTc-HDP bone scan. Hence, it is assumed that the diffuse and temporary cardiac activity was a result of transient iron overload. Bone scan using ^99mTc-DPD or ^99mTc-PYP is known for its several advantages in the diagnosis in CA. They not only have high sensitivity and specificity but also provide a non-invasive, whole-body evaluation and are readily accessible^5,6. Currently, multidisciplinary experts in cardiovascular imaging and cardiac amyloidosis recommend including bone scans for diagnosis of CA⁷. However, caution should be exercised in the interpretation of myocardial uptake in a bone scan, as altered biodistribution of radiotracer can occur in various medical conditions including iron overload 8-12. As bone scans are widely used in the diagnosis of CA, we present and share this image in order to avoid possible future misinterpretation.

References

Perugini, E.; Guidalotti, P.L.; Salvi, F.; Cooke, R.M.T.; Pettinato, C.; Riva, L.; Leone, O.; Farsad, M.; Ciliberti, P.; Bacchi-Reggiani, L.; et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology 2005, 46, 1076–1084. [Google Scholar] [CrossRef] [PubMed]
Treglia, G.; Glaudemans, A.; Bertagna, F.; Hazenberg, B.P.C.; Erba, P.A.; Giubbini, R.; Ceriani, L.; Prior, J.O.; Giovanella, L.; Slart, R. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2018, 45, 1945–1955. [Google Scholar] [CrossRef] [PubMed]
Brownrigg, J.; Lorenzini, M.; Lumley, M.; Elliott, P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail 2019, 6, 1041–1051. [Google Scholar] [CrossRef] [PubMed]
de Haro-del Moral, F.J.; Sánchez-Lajusticia, A.; Gómez-Bueno, M.; García-Pavía, P.; Salas-Antón, C.; Segovia-Cubero, J. Role of cardiac scintigraphy with ⁹⁹mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev Esp Cardiol (Engl Ed) 2012, 65, 440–446. [Google Scholar] [CrossRef] [PubMed]
Bokhari, S.; Castaño, A.; Pozniakoff, T.; Deslisle, S.; Latif, F.; Maurer, M.S. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013, 6, 195–201. [Google Scholar] [CrossRef] [PubMed]
Rapezzi, C.; Quarta, C.C.; Guidalotti, P.L.; Pettinato, C.; Fanti, S.; Leone, O.; Ferlini, A.; Longhi, S.; Lorenzini, M.; Reggiani, L.B.; et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011, 4, 659–670. [Google Scholar] [CrossRef] [PubMed]
Dorbala, S.; Ando, Y.; Bokhari, S.; Dispenzieri, A.; Falk, R.H.; Ferrari, V.A.; Fontana, M.; Gheysens, O.; Gillmore, J.D.; Glaudemans, A.; et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. J Card Fail 2019, 25, 854–865. [Google Scholar] [CrossRef] [PubMed]
Shin, E.; Oh, M.; Sung, C.; Kim, K.H.; Ryu, J.S. Altered Biodistribution of (99m)Tc-DPD on Bone Scan After Intravenous Iron Supplement. Nucl Med Mol Imaging 2017, 51, 347–349. [Google Scholar] [CrossRef] [PubMed]
Choy, D.; Murray, I.P.; Hoschl, R. The effect of iron on the biodistribution of bone scanning agents in humans. Radiology 1981, 140, 197–202. [Google Scholar] [CrossRef] [PubMed]
VanAntwerp, J.; Hall, J.; OMara, R.; Hilts, S. Bone scan abnormality produced by interaction of Tc-99m diphosphonate with iron dextran (Imferon). JOURNAL OF NUCLEAR MEDICINE: SOC NUCLEAR MEDICINE INC 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316; 1975:577-577.
Parker, J.A.; Jones, A.G.; Davis, M.A.; Mcilmoyle, G.; Tow, D.E. Reduced uptake of bone-seeking radiopharmaceuticals related to iron excess. Clinical Nuclear Medicine 1976, 1, 267–268. [Google Scholar] [CrossRef]
Forauer, A.R.; Grossman, S.J.; Joyce, J.M. Altered biodistribution of Tc-99m HMDP on bone scintigraphy from recent intravenous iron therapy. Clin Nucl Med 1994, 19, 817–818. [Google Scholar] [CrossRef] [PubMed]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

MDPI Initiatives

Important Links

Choose an area of interest and we will send you notifications of new preprints at your preferred frequency.

Disclaimer